The Cancer Research Institute (CRI), the European Network for Cancer Immunotherapy (ENCI), and the American Association for Cancer Research (AACR) co-organize the annual International Cancer lmmunotherapy Conference.
The European Network for Cancer Immunotherapy (ENCI) is a collaborative information and networking platform of the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the Italian Network for Tumor Biotherapy. ENCI harmonizes the activities of the European cancer immunotherapy community and fosters collaboration across organizations and countries. By providing and disseminating information, organizing scientific meetings and educating political decision makers, ENCI aims to advance the research and implementation of cancer immunotherapy in Europe.
The Association for Cancer Immunotherapy (CIMT) is Europe’s largest members-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians, and regulatory authorities who research and develop cancer immunotherapies. Founded in 2002, CIMT organizes annual meetings, working groups, advanced education seminars and symposia, and publishes white papers, guidelines, and textbooks on cancer immunotherapy.
European Academy of Tumor Immunology (EATI) promotes all areas of tumor immunology, considered as a continuum between fundamental, translational, and clinical research, as well as the practical implementation of diagnostic and therapeutic procedures in routine clinical practice. Founded in 2010, EATI counts on 199 “Academicians” and more than 1,300 members to organize scientific conferences, workshops and seminars, and to publish a dedicated journal, OncoImmunology.
The Italian Network for Tumor Biotherapy (NIBIT) was established in 2004, to create a cooperative network collecting and coordinating the activities of several Italian groups involved in cancer immunotherapy. The objectives of NIBIT are: (a) to promote and develop scientific, professional and operational interactions between professionals (academy, industry, regulatory agencies) involved in cancer biotherapy; (b) to develop and conduct clinical biotherapy studies; and (c) to inform cancer patients about clinical trials in the network.